Illumina Partners with PREMIA to Enhance Access to Comprehensive Genomic Profiling in Asia
On January 8, 2026, Illumina Taiwan Biotechnology Co., Ltd. (stock symbol: ILMN) announced a strategic collaboration with Precision Medicine Asia (PREMIA) to expand access to comprehensive genomic profiling (CGP) for eligible oncology patients within the Chang Gung Memorial Hospital (CGMH) network. This partnership not only aims to improve patient access to advanced genomic testing but also seeks to establish an Asia-wide clinical-genomic oncology database to advance the field of precision oncology.
Objectives of the Partnership
The collaboration is designed to ensure that all cancer patients in the CGMH system benefit from advanced genomic profiling technologies. According to Dr. Chang-Fu Kuo, Director of the Center for Artificial Intelligence in Medicine at CGMH, "Integrating CGP will streamline our testing workflows and help clinicians gain a better understanding of each patient’s tumor biology." This enables healthcare providers to leverage genomic insights for more personalized treatment plans.
Significance of Chang Gung Memorial Hospital
Chang Gung Memorial Hospital is a premier healthcare institution in Taiwan, serving approximately 2.7 million patients annually. The hospital currently supports over 300 industry-sponsored clinical trials, reflecting its commitment to incorporating the latest technologies into clinical practices.
Illumina's Commitment to Oncology
Jerry Cheng, General Manager for Taiwan, Hong Kong, and Macao at Illumina, emphasized the company's dedication to improving oncology profiling solutions. "This partnership will accelerate personalized care decisions at CGMH," stated Cheng. He also highlighted the potential to support translational research and drug development throughout Asia, leveraging the vast amount of data generated through this initiative.
Recent Developments in CGP Integration
In May 2024, CGP was formally incorporated into Taiwan’s National Health Insurance (NHI) program, marking a significant milestone in the country’s approach to integrated patient care and precision medicine.
About Illumina
Illumina is a global leader in DNA sequencing and array-based technologies, focused on improving human health by unlocking genomic power. Its products find applications across life sciences, oncology, reproductive health, and agriculture, among other sectors. To learn more about Illumina's offerings, visit their website at illumina.com.
About PREMIA
Established in 2018, PREMIA is the first company in Asia to offer a clinical-genomic data management platform aimed at accelerating the development of innovative diagnostics and therapeutics. The company collaborates with hospitals and pharmaceutical partners worldwide to enhance efficiencies and expand access to cutting-edge health solutions.
Contact Information
- Illumina: Sam Shen, Public Relations - PR@illumina.com
- PREMIA: Sydnie Reed, VP of Business Development - sreed@premia-inc.com